The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients

Minghui Zhang1,*, Yuandi Dong2,*, Haitao Liu3,*, Yan Wang4, Shu Zhao1, Qijia Xu1, Yan Wang1 & Qingyuan Zhang1

The prognostic value of programmed death-ligand 1 (PD-L1) in gastric cancer (GC) remains controversial. To clarify this problem, we performed a meta-analysis of research studies identified in the PubMed, EMBASE and the Cochrane Library databases. A total of 1,901 patients in 10 studies were enrolled in this meta-analysis, and the pooled hazard ratio (HR) of 1.64 (95% CI 1.11 to 2.43; P = 0.01) indicated that PD-L1 expression is associated with a shorter overall survival (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with tumour size (OR = 1.87, 95% CI 1.25 to 2.78; P = 0.002) and lymph node status (OR = 2.17, 95% CI 1.04 to 4.52; P = 0.04). However, PD-L1 had no correlation with gender, age, cancer location, differentiation, depth of invasion, and tumour stage. This meta-analysis indicates that PD-L1 expression is a valuable predictor of the prognosis of patients with GC. PD-L1 expression could be used for identifying a subgroup of patients, who would potentially benefit from targeted therapy against PD-1 or PD-L1. Well-designed large-cohort studies are needed to confirm these findings.

Gastric cancer is the one of the most common cancers around the world1. The majority of patients are diagnosed at an advanced stage, with 50%–75% presenting with regional lymph node metastasis, and the overall five-year survival rate of advanced stage GC patients is approximately 15%2. Although multimodality therapy has advanced, the prognosis and overall survival rate of patients with gastric cancer are still low3. Thus, to improve the prognosis of such patients, novel strategies need to be developed and established.

Programmed death 1 (PD-1), which belongs to the CD28 family, is a receptor expressed on the surface of activated T cells that regulates their proliferation and activation4. PD-L1 (also known as B7-H1) is the major ligand for PD-1 and is expressed in some tumour cells as well as by activated B cells and T cells, dendritic cells, myeloid cells, and endothelial cells5. The binding of PD-L1 to PD-1 leads to apoptosis or exhaustion in activated T cells6. PD-L1 expression is induced by tumour cells via variable mechanisms, thereby helping tumour cells escape from immune surveillance7. In addition, PD-L1 has a pivotal role in the conversion of naive T cells to regulatory T cells (Tregs) by inhibiting the Akt-mammalian target of rapamycin (mTOR) signalling8. The expression of PD-L1 has been correlated with poor clinical outcomes in several human cancers9–12. Given this background, a PD-1/PD-L1 pathway blockade by targeted-antibodies (against PD-1 or PD-L1) is a highly promising therapy and has elicited durable antitumor responses and long-term remission in recent clinical trials13.

Data on the prevalence and prognostic significance of PD-L1 expression in GC is very limited and remains controversial. We performed a meta-analysis to assess whether PD-L1 expression was correlated with the clinicopathological features and prognosis of GC patients.
Results

Study selection and characteristics. In the present study, 136 articles were identified by the initial search strategy. Through reading the study titles and abstracts, 118 records were removed because of duplicate studies and non-relevance with the theme. After we reviewed the full texts of the 18 potentially eligible articles in detail, 10 trials meeting the inclusion criteria were included in the final analysis. A flowchart depicting the study selection is shown in Fig. 1.

The characteristics of the included studies are shown in Table 1 and Supplementary Table S1. In total, 10 studies including 1,901 patients were included in the pooled analysis. OS was recorded in all studies. Study quality, as assessed by the Newcastle-Ottawa quality assessment scale, ranged from six to eight. Hence, the studies were of a relatively high quality.

PD-L1 as a prognostic factor for GC. We evaluated the correlation between PD-L1 expression and OS among the 1,901 patients from all ten included studies. The pooled HR for OS showed that PD-L1 expression was associated with poor OS (HR 1.64, 95% CI 1.11 to 2.43, P = 0.01) in GC with a 64% increase in the risk for mortality (Fig. 2). In addition, when using the percentage evaluation method, we found numerically inferior survival in the PD-L1 positive group if we took 51% (HR 2.40, 95% CI 1.70–3.40, P < 0.001) as well as 10% (HR 1.89, 95% CI 1.32–2.72, P < 0.001) as the cut-off value (Fig. 3).

The correlation between PD-L1 expression and clinicopathological features. Gender. We evaluated the correlation between PD-L1 expression and gender in a panel of 1,901 patients from all ten studies. Of 1,270 male patients, 494 (38.9%) were PD-L1 expression positive, and 228 (36.1%) of 631 female patients were PD-L1 expression positive. The pooled OR indicated no significant correlation between PD-L1 expression and gender (OR = 1.14; 95% CI = 0.92–1.40, P = 0.23) (Fig. 4A).

Age. The correlation between PD-L1 expression and age was analysed in two studies, including a total of 674 patients. Eighty patients (34.5%) were PD-L1 expression positive, among a total of 232 older patients (≥70 years), and 154 (34.8%) of 442 younger patients (<70 years) were PD-L1 expression positive. No significant association was found between PD-L1 expression and gender (OR = 1.12; 95% CI = 0.80–1.58, P = 0.51) (Fig. 4B).

Cancer location. Four out of the ten studies, including 425 patients, examined the relationship between PD-L1 expression and cancer location. Of 71 cardia patients, 41 (57.7%) were PD-L1 expression positive, and 178 patients (50.3%) were PD-L1 expression positive among 354 patients with gastric body and antrum cancers. The pooled OR indicated that PD-L1 expression had no clear correlation with cancer location (Fig. 4C).

Differentiation. Seven studies, including 1143 patients, were analysed for the correlation between PD-L1 expression and tumour differentiation. Of 655 poorly differentiated tumours, 291 (44.4%) were PD-L1 expression positive, and 216 (44.3%) of 488 moderately/well-differentiated cases were PD-L1 expression positive. No significant association was found between PD-L1 expression and tumour differentiation (OR = 0.96, 95% CI 0.59 to 1.59, P = 0.89) (Fig. 4D).

Tumour size. The relationship between PD-L1 expression and tumour size was evaluated in four studies including 409 patients. One hundred and three hundred (58.9%) patients were PD-L1 expression positive out of a total of 192 patients with large tumours (≥5 cm), and 94 (43.3%) out of a total of 217 patients with small tumours (<5 cm) were PD-L1 expression positive. Increased PD-L1 expression was found to be significantly associated with large tumour size (OR = 1.87, 95% CI 1.25 to 2.78, P = 0.002) (Fig. 4E).
Depth of invasion. Five studies with a total of 1,211 patients were analysed for the relationship between PD-L1 expression and the depth of tumour invasion. Positive PD-L1 expression was found in 255 (36%) out of 709 T3–4 level tumour invasion patients, while 116 (23.1%) out of 502 T1–2 level tumour invasion patients were PD-L1 expression positive. No significant relationship was detected between PD-L1 expression and the depth of tumour invasion (OR = 2.36, 95% CI 0.98 to 5.71, P = 0.06) (Fig. 4F).

Lymph node metastasis. Six studies comprising 987 patients were evaluated for the correlation between PD-L1 expression and lymph node metastasis. Of 679 patients with positive lymph node metastasis, 276 (40.6%) were PD-L1 expression positive, and 95 (30.8%) of 308 patients with negative lymph node metastasis were PD-L1 expression positive. The combined OR for the positive lymph node metastasis group versus the negative lymph node metastasis group was 2.17 (CI 1.04 to 4.52, P = 0.04) (Fig. 4G).

Stage. Four studies, including 1104 patients, were analysed for the association between PD-L1 expression and TNM stage. Two hundred and twenty-two (40.9%) of 543 stage III–IV patients were PD-L1 expression positive.

Table 1. Characteristics of the studies included in the meta-analysis. NO. = number of patients, NA = not available.

| Author   | Year | Country | No. | Stage | IHC evaluation method | Antibody | PD-L1 positive (%) | Outcome | HR estimation | Quality Assessment (score) |
|----------|------|---------|-----|-------|-----------------------|----------|-------------------|---------|---------------|----------------------------|
| Wu       | 2006 | China   | 102 | I-IV  | Percentage of positive cells and staining intensity | Shuzhou university, China NA MAB 2H11 | 43/102 (42.2) | OS | HR and 95% CI 2.80 (1.05–7.48) | 7 |
| Geng     | 2015 | China   | 100 | I-IV  | Percentage of positive cells and staining intensity | Novus, USA NA MAB 2H11 | H-score ≥ 3 | OS | HR and 95% CI 1.65 (1.16–2.37) | 7 |
| Hou      | 2014 | China   | 111 | I-IV  | Percentage of positive cells | Abcam, UK Rabbit PAB NA | ≥10% | OS | Survival curves 1.30(0.58–2.94) | 7 |
| Kim      | 2016 | Japan   | 243 | I-III | Percentage of positive cells and staining intensity | Abcam, UK Rabbit PAB NA | ≥10% and Moderate or strong staining | OS | Survival curves 0.63(0.36–1.09) | 7 |
| Qing     | 2015 | China   | 107 | I-III | Percentage of positive cells | GeneTex, USA NA PAB NA | ≥10% | OS | Survival curves 2.28(1.25–4.16) | 6 |
| Tamura   | 2015 | Japan   | 431 | I-IV  | Percentage of positive cells | Abcam, Japan Rabbit PAB NA | ≥51% | OS | HR and 95% CI 2.34 (1.63–3.37) | 7 |
| Wang     | 2015 | China   | 105 | NA    | Percentage of positive cells | Gene Tex, USA NA PAB NA | ≥10% | OS | HR and 95% CI 1.93 (1.12–3.32) | 6 |
| Zhang    | 2015 | China   | 132 | II-III| Staining intensity | Abcam, UK Rabbit PAB ab58810 | Moderate or intense staining | OS | Survival curves 2.7(1.40–5.23) | 7 |
| Christine| 2016 | German  | 465 | I-IV  | Percentage of positive cells and staining intensity | CellSignaling, USA Rabbit MAB E1L3N IRS ≥2 | 140/465(30.1) | OS | HR and 95% CI 0.75 (0.58–0.97) | 8 |
| Eto      | 2016 | Japan   | 105 | II-III| Percentage of positive cells | Abcam, UK Rabbit MAB ab174838 | ≥51% | OS | Survival curves 2.9(0.93–11.63) | 7 |

Table 1. Characteristics of the studies included in the meta-analysis. NO. = number of patients, NA = not available.

Figure 2. Forest plot describing the association between PD-L1 expression and OS of patients with gastric cancer.
and 152 (27.1%) out of 561 stage I-II patients were PD-L1 expression positive. No significant association was found between PD-L1 expression and stage (OR 2.36, 95% CI 0.83 to 6.69; $P = 0.11$) (Fig. 4H).

Heterogeneity was observed in the analysis of PD-L1 expression with histological differentiation ($P = 0.002$; $I^2 = 71\%$), the depth of tumour invasion ($P < 0.001$; $I^2 = 89\%$), lymph node status ($P < 0.001$; $I^2 = 81\%$), and tumour stage ($P < 0.001$; $I^2 = 92\%$). Thus, a random-effects model was employed for the analysis. The other analyses above were carried out using a fixed effects model.

**Publication bias and sensitivity analysis.** Egger’s and Begg’s test indicated no publication bias among these studies regarding the hazard ratio and overall survival, with $P$ values of 0.109 and 0.592, respectively (Fig. 5). Visual inspection of the funnel plots revealed no publication bias for gender (Fig. 6). Publication bias was not investigated when the number of studies was less than 10 because of the low sensitivity of the qualitative and quantitative tests.

A sensitivity analysis, in which one study was removed at a time, was performed to evaluate the stability of our results. The results demonstrated that no individual study significantly influenced the overall HRs. This suggested that the results of the present meta-analysis are credible.

**Discussion**

PD-L1 overexpression has been observed in various solid tumours, and several studies have demonstrated that the expression of PD-L1 plays a key role in cancer immune escape and the associated tumour progression and poor prognosis. These highlighted studies demonstrated that PD-L1 may serve as a potential prognostic and predictive biomarker. However, for patients with GC, the association between the expression of PD-L1 and their prognosis remains controversial. Multiple studies have indicated that positive PD-L1 expression is associated with a significantly poor OS, but other studies could not confirm this finding.

In the present meta-analysis, we pooled all available data from published studies to evaluate the correlation between PD-L1 expression and GC prognosis. Our results suggest that the up-regulation of the expression of PD-L1 protein contributes to the poor prognosis of GC. In 2015, Huang et al. also analysed the prognostic value of PD-L1 in gastrointestinal tract cancer. This study demonstrated that positive PD-L1 expression was a negative predictor for OS. Another recent meta-analysis also found that patients with PD-L1-positive expression had significantly shorter survival time compared with the PD-L1-negative group in East Asia. These results are consistent with our study. However, this meta-analysis did not include non-Asian populations, and did not present the correlation between PD-L1 expression and tumour size, lymph node status, gender, age, cancer location, differentiation, depth of invasion, and tumour stage. In addition, our study strictly screened the literature according to the inclusion criteria. To better analyze the correlation between PD-L1 expression and the clinical parameters, the inclusion criteria clearly require that the original article must provide two or more clinical parameters. Thus, Sun et al. did not meet the inclusion criteria and was excluded.

Based on our results, we consider PD-L1 overexpression to be a risk factor and a new biomarker for the prediction of GC prognosis. There are some possible explanations for the correlation between PD-L1 expression and a poor prognosis. First, the engagement of PD-L1 and PD-1 may induce activated T cell apoptosis, exhaustion, and interleukin-10 (IL-10) expression. Second, PD-L1 may function as a molecular shield to protect PD-L1 positive tumour cells from CD8+ T cell–mediated lysis. Third, PD-L1 can promote the generation of induced Tregs by down-regulating the mTOR, AKT, S6 and the phosphorylation of ERK2 and increases PTEN, thus restraining the activity of effector T-cells. These actions of PD-L1 expression on the tumour can promote T-cell tolerance.
**Figure 4.** Forest plots for the association between PD-L1 expression and clinicopathological features

(A) gender, (B) age, (C) cancer location, (D) differentiation, (E) tumor size, (F) dept of invasion, (G) lymph node metastasis, (H) stage.

| Study or Subgroup | Events | Male | Female | Odds Ratio | M.H. Fixed, 95% CI |
|-------------------|--------|------|--------|------------|-------------------|
| [A] Gender        |        |      |        |            |                   |
| Chris et al. 2015 | 80     | 290  | 31     | 175        | 17.7 (13.4, 23.2) |
| Cho et al. 2015  | 17     | 75   | 9      | 30         | 5.99 (2.06, 17.7) |
| Cao et al. 2015  | 42     | 41   | 20     | 29         | 0.014 (0.07, 0.30) |
| Hou et al. 2014  | 47     | 75   | 23     | 36         | 0.01 (0.04, 0.21) |
| Kim et al. 2015  | 68     | 152  | 38     | 91         | 1.03 (0.87, 1.21) |
| Qiu et al. 2015  | 37     | 72   | 17     | 55         | 1.12 (0.90, 1.40) |
| Tani et al. 2015 | 90     | 305  | 38     | 126        | 0.97 (0.62, 1.53) |
| Wang et al. 2015 | 36     | 71   | 16     | 34         | 1.36 (0.62, 2.92) |
| Wu et al. 2006   | 32     | 76   | 11     | 27         | 1.08 (0.44, 2.65) |
| Zhang et al. 2015| 48     | 94   | 22     | 38         | 0.67 (0.31, 1.49) |
| Total events     | 496    |      |        |            |                   |
| Total events     | 1370   |      |        | 1.14 (0.92, 1.40) |

| Study or Subgroup | Events | Total | Weight | M.H. Fixed, 95% CI |
|-------------------|--------|-------|--------|-------------------|
| [B] Age           |        |       |        |                   |
| Kim et al. 2015   | 21     | 63   | 85     | 190              | 0.81 (0.44, 1.51) |
| Tani et al. 2015  | 58     | 179  | 69     | 252              | 1.30 (0.36, 1.86) |
| Total events     | 80     | 154  |        |                   |
| Total events     | 232    | 442  | 100%   | 1.12 (0.80, 1.58) |

| Study or Subgroup | Events | Total | Weight | M.H. Fixed, 95% CI |
|-------------------|--------|-------|--------|-------------------|
| [C] Location      |        |       |        |                   |
| Hou et al. 2014   | 16     | 31   | 34     | 88               | 22.4% (9.93, 53.4) |
| Qiu et al. 2015   | 6      | 15   | 48     | 67               | 18.8% (0.41, 77)  |
| Wu et al. 2006    | 6      | 16   | 46     | 84               | 12.1% (1.07, 30)  |
| Total events     | 41     | 170  |        |                   |
| Total events     | 394    | 100% | 1.48 (0.96, 2.21) |

| Study or Subgroup | Events | Total | Weight | M.H. Fixed, 95% CI |
|-------------------|--------|-------|--------|-------------------|
| [D] Differentiation|       |       |        |                   |
| Kim et al. 2015   | 31     | 80   | 83     | 114              | 0.49 (0.26, 0.81) |
| Qiu et al. 2015   | 31     | 74   | 33     | 133              | 0.37 (0.19, 0.73) |
| Tani et al. 2015  | 69      | 234  | 59     | 197              | 0.99 (0.55, 1.79) |
| Wang et al. 2015  | 41      | 71   | 32     | 92               | 2.43 (0.33, 18.6) |
| Zhong et al. 2015 | 31      | 99   | 49     | 144              | 1.42 (0.86, 2.33) |
| Total events     | 102    | 315  |        |                   |
| Total events     | 455    | 100% | 0.06 (0.59, 1.59) |

| Study or Subgroup | Events | Total | Weight | M.H. Fixed, 95% CI |
|-------------------|--------|-------|--------|-------------------|
| [E] Tumor size    |        |       |        |                   |
| Qiu et al. 2015   | 12     | 28   | 14     | 36               | 19.3% (0.62, 57.7) |
| Wu et al. 2006    | 25      | 47   | 16     | 55               | 21.9% (1.05, 5.23) |
| Total events     | 37     | 75   |        |                   |
| Total events     | 192    | 217  | 1.87 (1.23, 2.78) |

| Study or Subgroup | Events | Total | Weight | M.H. Fixed, 95% CI |
|-------------------|--------|-------|--------|-------------------|
| [F] Dept of invasion|       |       |        |                   |
| Hou et al. 2014   | 37     | 54   | 33     | 57               | 20.5% (0.75, 3.42) |
| Qiu et al. 2015   | 12     | 28   | 14     | 36               | 13.0% (0.52, 3.70) |
| Wu et al. 2006    | 25      | 47   | 16     | 55               | 21.9% (1.05, 5.23) |
| Total events     | 38     | 73   |        |                   |
| Total events     | 192    | 217  | 1.87 (1.23, 2.78) |

| Study or Subgroup | Events | Total | Weight | M.H. Fixed, 95% CI |
|-------------------|--------|-------|--------|-------------------|
| [G] Lymph node metastasis|       |       |        |                   |
| Chris et al. 2016 | 47     | 94   | 22     | 38               | 0.67 (0.31, 1.49) |
| Cho et al. 2015  | 42     | 72   | 17     | 55               | 1.12 (0.90, 1.40) |
| Cao et al. 2015  | 42     | 72   | 17     | 55               | 1.12 (0.90, 1.40) |
| Hou et al. 2014  | 47     | 94   | 22     | 38               | 0.67 (0.31, 1.49) |
| Total events     | 80     | 154  |        |                   |
| Total events     | 232    | 442  | 100%   | 1.12 (0.80, 1.58) |

| Study or Subgroup | Events | Total | Weight | M.H. Fixed, 95% CI |
|-------------------|--------|-------|--------|-------------------|
| [H] Stage         |        |       |        |                   |
| Hou et al. 2014   | 47     | 94   | 22     | 38               | 0.67 (0.31, 1.49) |
| Qiu et al. 2015   | 37     | 72   | 17     | 55               | 1.12 (0.90, 1.40) |
| Wu et al. 2006    | 25      | 47   | 16     | 55               | 21.9% (1.05, 5.23) |
| Total events     | 37     | 73   |        |                   |
| Total events     | 192    | 217  | 1.87 (1.23, 2.78) |

---

A: For the overall effect, Z = 1.21 (P = 0.22).
B: For the overall effect, Z = 0.06 (P = 0.95).
C: For the overall effect, Z = 4.61 (P < 0.001).
D: For the overall effect, Z = 3.56 (P < 0.001).
E: For the overall effect, Z = 0.37 (P = 0.71).
F: For the overall effect, Z = 3.97 (P < 0.001).
G: For the overall effect, Z = 1.91 (P = 0.05).
H: For the overall effect, Z = 2.17 (P = 0.03).
and escape host immunity. In addition, due to the lack of uniform cut-off values, we conducted relative subgroup analyses. The pooled subgroup results showed that studies using 51% as the cut-off value had a greater difference in OS between PD-L1 positive and negative groups than those using 10%, and the HRs were 2.40 and 1.89, respectively.

Biomarker-driven selection of immunotherapy responders improves therapeutic efficacy, minimizes unnecessary exposure and reduces the financial burden on health systems. Recent studies show that high levels of PD-L1 expression are associated with higher clinical activity in patients with various cancer types treated with PD-1/PD-L1-targeted therapy\(^3\). In our study, we investigated the relationship between the expression of PD-L1 and clinicopathological factors. According to our pooled analysis, patients with larger tumours and positive lymph node metastasis tend to have higher levels of PD-L1 expression. These patients may benefit more from treatment targeting the PD-1/PD-L1 pathway. Additionally, larger tumours and positive lymph node metastasis are also associated with an advanced stage and a poor prognosis, and our results provide a scientific rationale and direct support for the current clinical application of anti-PD-1/PD-L1 immunotherapy in patients with advanced GC that otherwise lack effective treatment options. Our study also indirectly proves that high levels of PD-L1 protein

---

**Figure 5.** Egger’s and Begg’s funnel plot with 95% confidence intervals for OS publication bias testing.

**Figure 6.** Funnel blot was designed to visualize a potential publication bias for PD-L1 expression and gender.
expression are associated with poor GS prognosis. However, another recent meta-analysis showed that increased PD-L1 expression was significantly associated with a poorer tumour stage but not with a larger tumour size, which is inconsistent with our study. This discrepancy may be explained by the number of articles included in the meta-analysis: we included 10 articles while the previous meta-analysis included 25.

Efforts were made to conduct a comprehensive analysis, but there are limitations to our study. First, the cut-off values distinguishing positive and negative PD-L1 expression determined by IHC varied in different studies, which might cause heterogeneity among the overall results. The subgroup results should have addressed some of these concerns. Second, the distinct antibodies of PD-L1 expression among diverse studies might also impact the accurate estimation of the prognosis for gastric cancer. Standardized methods and definitions of PD-L1 positivity are clearly needed to facilitate studies of PD-L1 as a prognosis biomarker. Hence, a large multicenter study using the same antibody and cutoff for PD-L1 expression may be helpful to obtain more accurate results. Third, not all of the HRs with 95% CI was directly extracted from the studies, so we based our study on the data extracted from Kaplan-Meier curves, which compromises the precision of the data. Fourth, most of the eligible studies failed to provide data regarding progression free survival, so we only extracted OS data in our meta-analysis. Fifth, this meta-analysis was limited to articles published in English, possibly resulting in a publication bias. Despite the above limitations, this meta-analysis demonstrates the correlation between PD-L1 expression and the clinicopathological factors of GC. The results may lead to improvements in the outcomes of anti-PD-1/PD-L1 therapy due to this convenient stratification method.

In conclusion, our result indicated that PD-L1 overexpression is related to a poor prognosis, large tumours and the presence of lymph node metastasis. This information might prove to be helpful in screening candidates for anti-PD-1/PD-L1 therapy. Well-designed large cohort studies are needed to confirm these findings.

Methods

Literature search. Two authors (Zhang MH and Liu HT) independently carried out a comprehensive systematic search of published articles using the PubMed, EMBASE, and Cochrane databases, and any discrepancy was resolved by mutual discussion. The deadline for included articles was April 2016. The following keywords were used: (“PD-L1” or “B7-H1” or “CD274” or “Programmed Cell Death 1 Ligand 1 Protein) and (“gastric cancer” or “gastric neoplasms” or “stomach neoplasms”) with the limit “human” . Additional searches through Google Scholar and a manual search through the reference lists of relevant reviews were also performed.

Eligibility criteria. The criteria for inclusion were set out as the following: (1) All patients were histologically confirmed as GC; (2) PD-L1 expression was measured in GC tissue using immunohistochemistry; (3) Studies provided the correlation between PD-L1 and overall survival; (4) These studies provided a correlation between PD-L1 and clinicopathological features, including at least two parameters; (5) Studies provided sufficient information to estimate HR about OS; (6) Articles published as a full paper in English. Studies that failed to meet the inclusion criteria were excluded. When duplicate publications were identified, only the newest or most informative single article was selected.

Data extraction and quality assessment. The data were extracted independently by two reviewers (Zhang MH and Liu HT), and any disagreements between the two reviewers were resolved by consensus involving a third reviewer (Dong YD). The following information was extracted from each included trial: name of the first author, year of publication, country, number of patients, TNM stage, IHC evaluation method, antibody, cut-off, PD-L1-positive expression, clinicopathological parameters and the hazard ratios (HRs) and 95% confidence intervals (CIs) for OS. If the HRs were not directly reported, we contacted the authors of the primary studies for additional data. If the authors did not respond, we extracted data from survival curves.

A quality assessment was independently conducted for all of the included studies by two investigators (Wang Y and Zhao S) using the Newcastle–Ottawa Quality Assessment Scale (NOS), and any disagreements were resolved by discussion and consensus. The NOS comprises the following three parameters of quality: selection, comparability and outcome assessment. The maximum possible score is nine points, and NOS scores greater than six are considered indicative of high-quality studies.

Statistical methods. Hazard ratios (HRs) and their 95% CIs were combined to measure the effective value. If HRs and corresponding 95% CIs were not available, we calculated these data points from available numerical data using the methods reported by Parmar et al. Data from the Kaplan-Meier survival curves were read using Engauge Digitizer version 4.1. For the pooled analysis of the correlation between PD-L1 expression and the clinicopathological parameters, ORs and their 95% CIs were combined to obtain the effective value. Statistical heterogeneity was evaluated using the chi-squared test and I². Statistically significant heterogeneity was defined as a chi-squared P value < 0.1 or an I² statistic > 50%. If heterogeneity was observed, we used a random-effects model to reduce the impact of heterogeneity on the results. If heterogeneity was not observed, a fixed-effects model was used. The potential publication bias was assessed by Egger’s and Begg’s tests. All of the statistical analyses were performed using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 12.0 (Stata Corporation; College Station, TX, USA). P values < 0.05 were considered to indicate statistical significance. All P values and 95% CIs were two-sided.

References

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7–30 (2016).
2. Ajani, J. A. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw 6, 813–814 (2008).
3. Dittmar, Y. & Settmacher, U. Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World J Gastrointest Oncol 7, 292–302 (2015).
4. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. *Sci Transl Med* **8**, 328rv324 (2016).

5. Hansen, J. D. et al. The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. *Mol Immunol* **46**, 457–472 (2009).

6. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* **12**, 252–264 (2012).

7. Sannamed, M. F. & Chen, L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. *Cancer J* **20**, 256–261 (2014).

8. Francisco L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med* **206**, 3015–3029 (2009).

9. Wu, P., Wu, D., Li, L., Chai, Y. & Huang, J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. *PLoS One* **10**, e0131403 (2015).

10. Chowdhury, S. et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. *Oncotarget* (2016).

11. Cierna, Z. et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. *Ann Oncol* **27**, 300–305 (2016).

12. Katsuya, Y. et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. *Lung Cancer* **88**, 154–159 (2015).

13. Zheng, P. & Zhou, Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. *Biomark Cancer* **7**, 15–18 (2015).

14. Ioannidis, J. P. & Trikalinos, T. A. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. *Cmaj* **176**, 1091–1096 (2007).

15. Jin, Y., Zhao, J., Shi, X. & Yu, X. Prognostic value of programmed death ligand 1 in patients with solid tumors: A meta-analysis. *J Cancer Res Ther* **11** Suppl 1, C38–43 (2015).

16. Wu, C. et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. *Acta Histochem* **108**, 19–24 (2006).

17. Geng, Y. et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. *Int J Clin Oncol* **20**, 273–281 (2015).

18. Hou, J. et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. *Exp Mol Pathol* **96**, 284–291 (2014).

19. Qing, Y. et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. *Drug Des Devel Ther* **9**, 901–909 (2015).

20. Tamura, T. et al. Programmed Death-1 Ligand-1 (PD-L1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. *Anticancer Res* **35**, 5369–5376 (2015).

21. Wang, L. A., Wei, X., Li, Q. & Chen, L. The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography. *Tumour Biol* (2015).

22. Zhang, L. et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. *Int J Clin Exp Pathol* **8**, 11084–11091 (2015).

23. Eto, S. et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. *Gastric Cancer* **19**, 466–471 (2016).

24. Kim, J. W. et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. *Gastric Cancer* **19**, 42–52 (2016).

25. Christine, B. et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. *Oncotarget* (2016).

26. Huang, B. et al. The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. *Onco Targets Ther* **8**, 2617–2625 (2015).

27. Liu, Y. X. et al. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. *Onco Targets Ther* **9**, 2649–2654 (2016).

28. Sun, J. et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. *Tissue Antigens* **69**, 19–27 (2007).

29. Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol* **8**, 467–477 (2008).

30. Meng, X., Huang, Z., Teng, F., Xing, L. & Yu, J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. *Cancer Treat Rev* **41**, 868–876 (2015).

31. Xu, F. et al. Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. *Medicine (Baltimore)* **94**, e1911 (2015).

32. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* **25**, 603–605 (2010).

33. Parmar, M. K., Torri, V. & Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med* **17**, 2815–2834 (1998).

Acknowledgements

This study was supported by grants from the Natural Science Foundation of Heilongjiang Province No. H201335

Author Contributions

M.H.Z. and Q.Y.Z. designed this study; M.H.Z. and H.T.L. searched databases and collected full-text papers; M.H.Z., H.T.L. and Y.D.D. extracted and analyzed data; Y.W., S.Z. and Q.J.X. wrote the manuscript; All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhang, M. et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. *Sci. Rep.* **6**, 37933; doi: 10.1038/srep37933 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
